A Phase I Clinical Study of MK-0683 in Patients With Malignant Lymphoma
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2015
At a glance
- Drugs Vorinostat (Primary)
- Indications Lymphoma
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 29 May 2012 Actual patient number added 10 according to ClinicalTrials.gov.
- 22 May 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
- 22 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.